Xin Huang1, Bin Meng, Javeed Iqbal, B Belinda Ding, Anamarija M Perry, Wenfeng Cao, Lynette M Smith, Chengfeng Bi, Chunsun Jiang, Timothy C Greiner, Dennis D Weisenburger, Lisa Rimsza, Andreas Rosenwald, German Ott, Jan Delabie, Elias Campo, Rita M Braziel, Randy D Gascoyne, James R Cook, Raymond R Tubbs, Elaine S Jaffe, James O Armitage, Julie M Vose, Louis M Staudt, Timothy W McKeithan, Wing C Chan, B Hilda Ye, Kai Fu. 1. Xin Huang, Bin Meng, Wenfeng Cao, and Kai Fu, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Tianjin; Chengfeng Bi, West China Hospital, West China School of Medicine of Sichuan University, Chengdu, China; Xin Huang, Bin Meng, Javeed Iqbal, Anamarija M. Perry, Wenfeng Cao, Lynette M. Smith, Chengfeng Bi, Chunsun Jiang, Timothy C. Greiner, Dennis D. Weisenburger, James O. Armitage, Julie M. Vose, Timothy W. McKeithan, Wing C. Chan, and Kai Fu, University of Nebraska Medical Center, Omaha, NE; B. Belinda Ding and B. Hilda Ye, Albert Einstein College of Medicine, Bronx, NY; Lisa Rimsza, University of Arizona, Tucson, AZ; Andreas Rosenwald, University of Würzburg, Würzburg, Germany; German Ott and Jan Delabie, Rikshospitalet-Radiumhospitalet Medical Center, University of Oslo, Oslo, Norway; Elias Campo, Hospital Clinic, University of Barcelona, Barcelona, Spain; Rita M. Braziel, Oregon Health and Science University, Portland, OR; Randy D. Gascoyne, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; James R. Cook and Raymond R. Tubbs, Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH; Elaine S. Jaffe and Louis M. Staudt, Center for Cancer Research, National Cancer Institute, Bethesda, MD.
Abstract
PURPOSE: We previously reported that constitutive STAT3 activation is a prominent feature of the activated B-cell subtype of diffuse large B-cell lymphomas (ABC-DLBCL). In this study, we investigated whether STAT3 activation can risk stratify patients with DLBCL. PATIENTS AND METHODS: By an immunohistochemical method, we investigated phosphotyrosine STAT3 (PY-STAT3) expression from 185 patients with DLBCL treated with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone). Cell line-based siRNA experiments were also performed to generate an 11-gene, PY-STAT3 activation signature, which was used to study a previously published cohort of 222 patients with DLBCL. The STAT3 activation status determined by these two methods and by STAT3 mRNA levels were then correlated with survival. RESULTS: PY-STAT3 was detected in 37% of DLBCL and enriched in ABC-DLBCL cases (P = .03). PY-STAT3 positivity significantly correlated with poor overall survival (OS; P = .01) and event-free survival (EFS; P = .006). Similar observations were made for high levels of STAT3 mRNA. In multivariable analysis, PY-STAT3 status (P = .02), International Prognostic Index (P = .02), and BCL2 expression (P = .046) were independent prognosticators of OS in this cohort. Among the cell-of-origin subgroups, PY-STAT3 was associated with poor EFS among non-germinal center B-cell DLBCL cases only (P = .027). Similarly, the 11-gene STAT3 activation signature correlated with poor survival in the entire DLBCL cohort (OS, P < .001; EFS, P < .001) as well as the ABC-DLBCL subgroup (OS, P = .029; EFS, P = .025). CONCLUSION: STAT3 activation correlated with poor survival in patients with DLBCL treated with R-CHOP, especially those with tumors of the ABC-DLBCL subtype.
PURPOSE: We previously reported that constitutive STAT3 activation is a prominent feature of the activated B-cell subtype of diffuse large B-cell lymphomas (ABC-DLBCL). In this study, we investigated whether STAT3 activation can risk stratify patients with DLBCL. PATIENTS AND METHODS: By an immunohistochemical method, we investigated phosphotyrosine STAT3 (PY-STAT3) expression from 185 patients with DLBCL treated with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone). Cell line-based siRNA experiments were also performed to generate an 11-gene, PY-STAT3 activation signature, which was used to study a previously published cohort of 222 patients with DLBCL. The STAT3 activation status determined by these two methods and by STAT3 mRNA levels were then correlated with survival. RESULTS: PY-STAT3 was detected in 37% of DLBCL and enriched in ABC-DLBCL cases (P = .03). PY-STAT3 positivity significantly correlated with poor overall survival (OS; P = .01) and event-free survival (EFS; P = .006). Similar observations were made for high levels of STAT3 mRNA. In multivariable analysis, PY-STAT3 status (P = .02), International Prognostic Index (P = .02), and BCL2 expression (P = .046) were independent prognosticators of OS in this cohort. Among the cell-of-origin subgroups, PY-STAT3 was associated with poor EFS among non-germinal center B-cell DLBCL cases only (P = .027). Similarly, the 11-gene STAT3 activation signature correlated with poor survival in the entire DLBCL cohort (OS, P < .001; EFS, P < .001) as well as the ABC-DLBCL subgroup (OS, P = .029; EFS, P = .025). CONCLUSION:STAT3 activation correlated with poor survival in patients with DLBCL treated with R-CHOP, especially those with tumors of the ABC-DLBCL subtype.
Authors: Javeed Iqbal; Paul N Meyer; Lynette M Smith; Nathalie A Johnson; Julie M Vose; Timothy C Greiner; Joseph M Connors; Louis M Staudt; Lisa Rimsza; Elaine Jaffe; Andreas Rosenwald; German Ott; Jan Delabie; Elias Campo; Rita M Braziel; James R Cook; Raymond R Tubbs; Randy D Gascoyne; James O Armitage; Dennis D Weisenburger; Wing C Chan Journal: Clin Cancer Res Date: 2011-09-20 Impact factor: 12.531
Authors: M Narimatsu; H Maeda; S Itoh; T Atsumi; T Ohtani; K Nishida; M Itoh; D Kamimura; S J Park; K Mizuno; J Miyazaki; M Hibi; K Ishihara; K Nakajima; T Hirano Journal: Mol Cell Biol Date: 2001-10 Impact factor: 4.272
Authors: Roberto Chiarle; William J Simmons; Honjying Cai; Girish Dhall; Alberto Zamo; Regina Raz; James G Karras; David E Levy; Giorgio Inghirami Journal: Nat Med Date: 2005-05-15 Impact factor: 53.440
Authors: Erik A Nelson; Sarah R Walker; Alicia Kepich; Laurie B Gashin; Teru Hideshima; Hiroshi Ikeda; Dharminder Chauhan; Kenneth C Anderson; David A Frank Journal: Blood Date: 2008-09-29 Impact factor: 22.113
Authors: Georg Lenz; George W Wright; N C Tolga Emre; Holger Kohlhammer; Sandeep S Dave; R Eric Davis; Shannon Carty; Lloyd T Lam; A L Shaffer; Wenming Xiao; John Powell; Andreas Rosenwald; German Ott; Hans Konrad Muller-Hermelink; Randy D Gascoyne; Joseph M Connors; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Lisa M Rimsza; Richard I Fisher; Dennis D Weisenburger; Wing C Chan; Louis M Staudt Journal: Proc Natl Acad Sci U S A Date: 2008-09-02 Impact factor: 11.205
Authors: William W L Choi; Dennis D Weisenburger; Timothy C Greiner; Miguel A Piris; Alison H Banham; Jan Delabie; Rita M Braziel; Huimin Geng; Javeed Iqbal; Georg Lenz; Julie M Vose; Christine P Hans; Kai Fu; Lynette M Smith; Min Li; Zhongfeng Liu; Randy D Gascoyne; Andreas Rosenwald; German Ott; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; David L Jaye; Louis M Staudt; Wing C Chan Journal: Clin Cancer Res Date: 2009-08-25 Impact factor: 12.531
Authors: G Lenz; G Wright; S S Dave; W Xiao; J Powell; H Zhao; W Xu; B Tan; N Goldschmidt; J Iqbal; J Vose; M Bast; K Fu; D D Weisenburger; T C Greiner; J O Armitage; A Kyle; L May; R D Gascoyne; J M Connors; G Troen; H Holte; S Kvaloy; D Dierickx; G Verhoef; J Delabie; E B Smeland; P Jares; A Martinez; A Lopez-Guillermo; E Montserrat; E Campo; R M Braziel; T P Miller; L M Rimsza; J R Cook; B Pohlman; J Sweetenham; R R Tubbs; R I Fisher; E Hartmann; A Rosenwald; G Ott; H-K Muller-Hermelink; D Wrench; T A Lister; E S Jaffe; W H Wilson; W C Chan; L M Staudt Journal: N Engl J Med Date: 2008-11-27 Impact factor: 91.245
Authors: Andreas Herrmann; Christoph Lahtz; Toshikage Nagao; Joo Y Song; Wing C Chan; Heehyoung Lee; Chanyu Yue; Thomas Look; Ronja Mülfarth; Wenzhao Li; Kurt Jenkins; John Williams; Lihua E Budde; Stephen Forman; Larry Kwak; Thomas Blankenstein; Hua Yu Journal: Cancer Res Date: 2017-07-17 Impact factor: 12.701
Authors: Javeed Iqbal; Yulei Shen; Xin Huang; Yanyan Liu; Laura Wake; Cuiling Liu; Karen Deffenbacher; Cynthia M Lachel; Chao Wang; Joseph Rohr; Shuangping Guo; Lynette M Smith; George Wright; Sharathkumar Bhagavathi; Karen Dybkaer; Kai Fu; Timothy C Greiner; Julie M Vose; Elaine Jaffe; Lisa Rimsza; Andreas Rosenwald; German Ott; Jan Delabie; Elias Campo; Rita M Braziel; James R Cook; Raymond R Tubbs; James O Armitage; Dennis D Weisenburger; Louis M Staudt; Randy D Gascoyne; Timothy W McKeithan; Wing C Chan Journal: Blood Date: 2014-12-10 Impact factor: 22.113
Authors: Chi Young Ok; Jiayu Chen; Zijun Y Xu-Monette; Alexandar Tzankov; Ganiraju C Manyam; Ling Li; Carlo Visco; Santiago Montes-Moreno; Karen Dybkær; April Chiu; Attilio Orazi; Youli Zu; Govind Bhagat; Kristy L Richards; Eric D Hsi; William W L Choi; J Han van Krieken; Jooryung Huh; Xiaoying Zhao; Maurilio Ponzoni; Andrés J M Ferreri; Francesco Bertoni; John P Farnen; Michael B Møller; Miguel A Piris; Jane N Winter; L Jeffrey Medeiros; Ken H Young Journal: Clin Cancer Res Date: 2014-08-14 Impact factor: 12.531
Authors: Yuan Ren; Chengfeng Bi; Xiaohong Zhao; Tint Lwin; Cheng Wang; Ji Yuan; Ariosto S Silva; Bijal D Shah; Bin Fang; Tao Li; John M Koomen; Huijuan Jiang; Julio C Chavez; Lan V Pham; Praneeth R Sudalagunta; Lixin Wan; Xuefeng Wang; William S Dalton; Lynn C Moscinski; Kenneth H Shain; Julie Vose; John L Cleveland; Eduardo M Sotomayor; Kai Fu; Jianguo Tao Journal: J Clin Invest Date: 2018-11-05 Impact factor: 14.808